• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zymeworks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    1/8/25 4:16:05 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYME alert in real time by email
    8-K
    false 0001937653 0001937653 2025-01-08 2025-01-08

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): January 8, 2025

     

     

    Zymeworks Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41535   88-3099146
    (State or other jurisdiction
    of incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    108 Patriot Drive, Suite A

    Middletown, Delaware

      19709
    (Address of principal executive offices)   (Zip Code)

    (302) 274-8744

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.00001 per share   ZYME   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 2.02 Results of Operations and Financial Condition.

    On January 8, 2025, Zymeworks Inc. (the “Company”) announced certain information relating to the Company’s financial condition as of December 31, 2024, including its preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and marketable securities, of approximately $324 million. The Company also announced that it expects such cash resources, when combined with certain anticipated regulatory milestone payments, to fund the Company’s current planned operations into the second half of 2027 (such information, the “Financial Condition Information”). The Financial Condition Information is set forth in a press release issued by the Company on January 8, 2025, including under the caption “Updated Cash Runway Guidance”. The preliminary and unaudited estimate of cash resources is based on management’s initial analysis of operations for the quarter and year ended December 31, 2024, and is subject to further internal review and audit by the Company’s external auditors. A copy of this press release is attached hereto as Exhibit 99.1.

    The press release is incorporated herein by reference, except for the Financial Condition Information, which information is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 8.01 Other Events.

    On January 8, 2025, the Company issued a press release announcing a corporate update on its strategic priorities and other matters. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference, except for the Financial Condition Information, which information is furnished as described under Item 2.02 above.

    Forward-Looking Statements

    This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements are identified by such words as “believe,” “expect,” “anticipate” and words of similar import and are based on current expectations that involve risks and uncertainties, such as the Company’s plans, projections, objectives, expectations and intentions. All statements other than historical or current facts are forward-looking statements, including, without limitation, statements about the Company’s preliminary and unaudited estimate of cash resources, which consist of cash, cash equivalents and marketable securities, and the Company’s anticipated funding of its current operations and related expected timelines. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These statements, like all statements in this report, speak only as of their date. Furthermore, the Company is in the process of finalizing its financial results for the fourth quarter and fiscal year ended December 31, 2024, and therefore the Company’s finalized and audited results and final analysis of those results are not yet available. The preliminary expectations regarding year-end cash, cash equivalents, and marketable securities are the responsibility of management, are subject to management’s review and actual results could differ from management’s expectations. The actual results are also subject to audit by the Company’s independent registered public accounting firm and no assurance is given by the Company’s independent registered public accounting firm on such preliminary expectations. You should not draw any conclusions as to any other financial results as of and for the year ended December 31, 2024, based on the foregoing estimates.

    Item 9.01 Financial Statements and Exhibits

    (d) Exhibits

     

    Exhibit No.    Description
    99.1    Press Release dated January 8, 2025.
    104    Cover Page Interactive Data File (embedded as Inline XBRL document).

     

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

           

    ZYMEWORKS INC.

        (Registrant)
    Date: January 8, 2025     By:  

    /s/ Kenneth Galbraith

       

    Name:

    Title:

     

    Kenneth Galbraith

    Chair of the Board of Directors, President and Chief Executive Officer

     

    3

    Get the next $ZYME alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYME

    DatePrice TargetRatingAnalyst
    12/12/2025$33.00Equal Weight → Overweight
    Wells Fargo
    12/3/2025$32.00Mkt Outperform
    Citizens JMP
    10/24/2025$15.00Equal Weight
    Wells Fargo
    10/14/2025$26.00Neutral → Buy
    H.C. Wainwright
    10/10/2025$30.00Buy
    B. Riley Securities
    5/20/2025Buy
    TD Cowen
    12/16/2024$18.00Neutral → Overweight
    Analyst
    11/7/2024$10.00 → $25.00Market Perform → Outperform
    Leerink Partners
    More analyst ratings

    $ZYME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Mekan Sabeen claimed no ownership of stock in the company (SEC Form 3)

    3 - Zymeworks Inc. (0001937653) (Issuer)

    2/2/26 8:37:00 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Operating Officer Hollywood Mark converted options into 17,666 shares and sold $138,762 worth of shares (6,120 units at $22.67), increasing direct ownership by 10% to 132,913 units (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    1/13/26 5:11:03 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Hollywood Mark claimed ownership of 121,367 shares (SEC Form 3)

    3 - Zymeworks Inc. (0001937653) (Issuer)

    1/13/26 5:04:03 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    SEC Filings

    View All

    SEC Form S-8 filed by Zymeworks Inc.

    S-8 - Zymeworks Inc. (0001937653) (Filer)

    3/2/26 7:23:59 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure

    8-K - Zymeworks Inc. (0001937653) (Filer)

    3/2/26 6:28:54 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Zymeworks Inc.

    10-K - Zymeworks Inc. (0001937653) (Filer)

    3/2/26 6:28:07 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zymeworks upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Zymeworks from Equal Weight to Overweight and set a new price target of $33.00

    12/12/25 8:37:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Zymeworks with a new price target

    Citizens JMP initiated coverage of Zymeworks with a rating of Mkt Outperform and set a new price target of $32.00

    12/3/25 8:41:52 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo resumed coverage on Zymeworks with a new price target

    Wells Fargo resumed coverage of Zymeworks with a rating of Equal Weight and set a new price target of $15.00

    10/24/25 9:02:46 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

    Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks' balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028 NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Zymeworks Inc. (NASDAQ:ZYME) today announced an agre

    3/2/26 6:10:00 AM ET
    $RPRX
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

    Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks' balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash runway beyond 2028 VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agre

    3/2/26 6:01:00 AM ET
    $RPRX
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and ChinaAdditional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J)$62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program$250.0 million non-recourse royalty-backed

    3/2/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    5/19/25 6:35:05 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/18/25 3:17:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

    4 - Zymeworks Inc. (0001937653) (Issuer)

    4/7/25 6:34:11 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Leadership Updates

    Live Leadership Updates

    View All

    Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

    VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks' Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovati

    11/18/25 1:01:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

    VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer. In this role, Dr. Schayowitz will report directly to Zymeworks' Chair & Chief Executive Officer, Kenneth Galbraith, and work closely with the Zymeworks R&D and Business Development teams to advance the Company's broad portfolio of nominated product candidates, while also

    10/9/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

    VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointments of Greg Ciongoli and Robert E. Landry to the Company's Board of Directors, effective August 10, 2025. Mr. Ciongoli and Mr. Landry were also appointed as members of the audit committee of the Board of Directors. "Greg and Bob bring extensive financial and strategic leadership expertise that will be invaluable to Zymeworks, as we continu

    8/11/25 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Financials

    Live finance-specific insights

    View All

    Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) during 1Q 2026 in the U.S. with potential launch in 2H 2026Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the U.S., Europe, Japan, and ChinaAdditional clinical data for pasritamig in prostate cancer presented at ASCO-GU in February 2026 by Johnson & Johnson Innovative Medicine (J&J)$62.5 million utilized for share repurchases as of March 2, 2026 under the current authorized share repurchase program$250.0 million non-recourse royalty-backed

    3/2/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

    VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 2, 2026 at 8:30 am Eastern Time (ET). About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a

    2/12/26 6:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

    Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholdersStrategic initiative follows positive topline results from pivotal Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab in first-line gastroesophageal adenocarcinoma (GEA) and pasritamig advancing to registration studies by J&J Innovative Medicine (J&J)Eligible to receive up to $440.0 million in potential near-term milestone payments upon successful global regulatory approvals of Ziihera® in GEA Successful commercialization of Ziihera and execution of partnership strategy are expected to drive substantial royalty and milestone revenues with carefully managed R&D

    11/18/25 1:00:00 AM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZYME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 9:00:57 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zymeworks Inc.

    SC 13G/A - Zymeworks Inc. (0001937653) (Subject)

    11/14/24 4:27:20 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Zymeworks Inc.

    SC 13G - Zymeworks Inc. (0001937653) (Subject)

    11/13/24 4:30:24 PM ET
    $ZYME
    Biotechnology: Pharmaceutical Preparations
    Health Care